论文部分内容阅读
【目的】探讨生物荧光体外肿瘤药敏检测技术(ATP-TCA)指导下化疗对复发性卵巢上皮性癌的临床价值。【方法】将本院100例复发性卵巢上皮性癌患者随机分为观察组与对照组，每组50例。观察组患者在ATP-TCA指导下进行化疗，对照组给予常规化疗，比较两组患者化疗有效率、化疗毒副作用以及无进展生存时间。【结果】观察组有效率(RR)、疾病控制率(DCR)分别为70.00%(35/50)、78.00%(39/50)，与对照组相比明显上升，且两组相比较差异有显著性(P0.05)；观察组与对照组患者的中位生存期分别为4、6个月，两组相比较差异有显著性(P<0.01)。【结论】对复发性卵巢上皮性癌患者在ATP-TCA指导下进行化疗可明显提高化疗有效率与中位无进展生存期，且不会增加化疗毒副作用，值得临床推广应用。“,”Objective]To explore the bioluminescence in vitro tumor susceptibility testing technology (ATP-TCA)under the guidance of the clinical value of chemotherapy for recurrent ovarian epithelial carcinoma.[Meth-ods]100 cases of recurrent epithelial ovarian cancer patients were randomly divided into observation group and con-trol group with 50 cases in each group.Observation group of patients were under the guidance of ATP-TCA chem-otherapy,while the control group was given conventional chemotherapy.The chemotherapy efficiency,side effects of chemotherapy,and pregression-free survival times were compared between the two groups.[Results]The obser-vation group recurrence RR and DCR were 70.00% and 78.00%,respectively.These values were much higher than in the control group,with the difference being statistically significantly (P 0.05).The patients in both the observation group and control group had a median survival expectancy of of 4 and 6 months,respectively-the difference being statisti-cally significant (P <0.01).[Conclusion]The guidance of ATP-TCA in patients with recurrent epithelial oarian cancer chemotherapy can significantly improve chemotherapy PFS and efficiency,and will not increase the side effects of chemotherapy.It is worthy of clinical popularization and application.